Cenobamate, discovered and developed by SK Biopharmaceuticals and SK life science, was approved by the FDA for the treatment of focal-onset seizures in adults in 2019 and is commercially available in the US under the brand name XCOPRI (cenobamate tablets) CV.

Epilepsy affects over 600,000 people in the UK, which is approximately one in every 100 people. In some cases, epileptic seizures can be fatal, and an estimated 1,000 people die in the UK every year because of the condition.

Stuart Mulheron, General Manager UK & Ireland, Angelini Pharma, commented: “Angelini Pharma is committed to improving seizure control for people living with epilepsy. Today’s positive recommendation for cenobamate by NICE is testament to the strength of key trial data and offers the prospect of better management for people affected by uncontrolled seizures in the UK. The FAD is a significant milestone for cenobamate and takes us closer towards reimbursement in England and Wales.”